GLP-1 Medications (Ozempic, Wegovy, Mounjaro, Zepbound) and Your Eyes: What Patients Should Know

This article is for educational purposes only and is not medical advice. Please see the full disclaimer at the end.

GLP-1 medications have changed how we treat type 2 diabetes and obesity. Millions of people now take semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound), and for many, the benefits are significant: better blood sugar control, meaningful weight loss, and lower cardiovascular risk.

As eye doctors, we are also hearing a growing number of questions from patients: "Can this medication hurt my eyes?" The short answer is that serious eye problems are uncommon, but there are a few things every patient on these medications should understand.

1. Temporary blurry vision when you first start

This is the most common eye-related complaint, and it is usually harmless.

When blood sugar has been high for a long time, the natural lens inside the eye absorbs extra fluid and swells slightly. When a GLP-1 medication brings blood sugar down quickly, the lens changes shape again. The result is a temporary shift in your glasses prescription: things may look blurry, or your current glasses may suddenly feel "wrong."

This typically settles within a few weeks to a couple of months as blood sugar stabilizes. Our advice: do not rush to buy new glasses or schedule LASIK or cataract surgery during this period. Wait until your blood sugar and weight have leveled off so that measurements are accurate.

2. Worsening of existing diabetic retinopathy

This is the best-documented eye risk, and it applies mainly to patients who already have diabetic eye disease.

In the SUSTAIN-6 trial, patients taking semaglutide had more diabetic retinopathy complications (3.0%) than those on placebo (1.8%). The FDA label for Ozempic carries a specific warning about this. The likely cause is not the drug itself, but the speed of blood sugar improvement. This same "early worsening" has been seen for decades with insulin and other treatments that lower blood sugar rapidly.

The good news: several recent real-world studies, including one from the Cleveland Clinic Cole Eye Institute, found no increase in retinopathy progression in the average patient. The concern is concentrated in people who already have moderate to severe retinopathy when they start.

If you have diabetes, get a dilated retinal exam before or shortly after starting a GLP-1 medication, and keep up with follow-up exams while your blood sugar is changing. If you already have retinopathy, your eye doctor may want to see you more often during the first year.

3. NAION: a rare but serious optic nerve condition

Non-arteritic anterior ischemic optic neuropathy (NAION) is sometimes described as a "stroke of the optic nerve." Blood flow to the nerve is reduced, causing sudden, painless vision loss in one eye, often noticed on waking. Vision loss from NAION is usually permanent.

In 2024, researchers at Harvard's Mass Eye and Ear reported that patients on semaglutide had a higher rate of NAION than similar patients on other medications. Since then, results have been mixed. Some large database studies found no link; others found a small increase. A 2025 study of over 150,000 matched patients with type 2 diabetes found NAION in 0.04% of those taking semaglutide or tirzepatide versus 0.02% of those on other diabetes drugs over two years.

In June 2025, the European Medicines Agency completed its review and concluded that NAION is a real but "very rare" side effect of semaglutide, affecting up to 1 in 10,000 people, roughly a doubling of an already small baseline risk. European product labels were updated accordingly. In the United States, the FDA has not added NAION to the label as of this writing, though the topic remains under study and litigation is ongoing.

What this means for you: the absolute risk is very low, but the consequence is serious. Patients with additional NAION risk factors, such as a small, "crowded" optic nerve, sleep apnea, high blood pressure, or a prior NAION in one eye, should discuss this with both their prescribing doctor and their eye doctor before starting.

4. Macular degeneration: the evidence is unclear

Some 2025 studies suggested GLP-1 users with diabetes might have a higher rate of wet (neovascular) age-related macular degeneration, while other studies found GLP-1 users progressed to advanced AMD less often. These results conflict, and the studies were not designed to prove cause and effect. For now, there is no reason for patients with early AMD to avoid these medications, but it is another reason to keep regular eye exams.

5. Dry eye and changes around the eyes

Rapid weight loss can reduce fat around the eye socket, which some patients notice as a more hollow or sunken appearance. GLP-1 medications can also cause dehydration through nausea and reduced fluid intake, which may worsen dry eye symptoms. These effects are not dangerous and are usually manageable with hydration and lubricating drops.

Symptoms that need same-day attention

Contact an eye doctor immediately (do not wait for your next scheduled visit) if you experience any of the following while on a GLP-1 medication:

• Sudden loss of vision or a dark area in your vision in one eye, especially on waking
• A sudden increase in floaters or flashes of light
• A curtain or shadow moving across your vision
• Vision that gets rapidly worse over hours or days

If NAION is suspected, the medication is typically stopped, and the decision about whether to continue should involve both your prescribing doctor and your eye doctor.

Our recommendations

1. Get a baseline eye exam before or within the first few months of starting a GLP-1 medication, especially if you have diabetes.
2. Tell your eye doctor you are taking one of these medications. It matters for how we interpret changes in your vision and prescription.
3. Wait for stability before elective eye surgery. If you are considering LASIK, PRK, or cataract surgery with a premium lens, measurements are most accurate once your weight and blood sugar have been steady for at least two to three months.
4. Keep the big picture in mind. For most patients, the health benefits of these medications outweigh the eye risks, and good diabetes control protects your eyes over the long term.

Questions?

If you are on a GLP-1 medication and have noticed changes in your vision, or you simply want a baseline exam for peace of mind, we are happy to see you. Call Eye Care of East Bay at (925) 705-7299 or request an appointment online.

Medical Disclaimer

The information in this article is provided for general educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and it does not create a doctor-patient relationship between you and Eye Care of East Bay or any of its physicians. Medical research on GLP-1 medications is evolving, and the information here reflects what was publicly available at the time of writing; it may not reflect the most current findings.

Never disregard professional medical advice, delay seeking it, or start, stop, or change any prescribed medication because of something you have read here. Always consult your prescribing physician and a qualified eye care professional about your individual situation. If you believe you are experiencing a medical emergency, including sudden vision loss, call 911 or seek immediate medical care.